Bristol-Myers Squibb Buys Medarex for $2.4 billion
In an effort to boost its biologics pipeline, Bristol-Myers Squibb (BMS, New York, NY) will acquire Medarex (Princeton, NJ) for approximately $2.4 billion.
In an effort to boost its biologics pipeline, Bristol-Myers Squibb (BMS, New York, NY) will acquire Medarex (Princeton, NJ) for approximately $2.4 billion. With the acquisition of Medarex, BMS will gain rights to several biologics under development, access to two new technology platforms, and royalties for drugs already on the market.
BMS will gain rights to seven antibodies in clinical trials under Medarex’s sole sponsorship and three other antibodies being co-developed with other partners. It will also have rights to preclinical assets in various stages of development by Medarex, including the monoclonal antibody drug ipilimumab, currently in Phase 3 trials for metastatic melanoma and Phase 2 trials for lung cancer.
Besides a robust pipeline, BMS will have access to Medarex’s UltiMAb human antibody development system and next-generation antibody-drug conjugate (ADC) technology for use in immunology and oncology therapeutic areas. BMS will also get royalties based on a percentage of sales for Simponi, Stelara, and Ilaris, Medarex’s currently marketed therapies.
Under the terms of the definitive merger agreement, BMS will commence a cash tender offer on or about July 27, 2009, to purchase all of the outstanding shares of Medarex common stock for $16.00 per share in cash. The merger agreement contains a provision under which Medarex has agreed not to solicit any competing offers for the company.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
